{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:08:57Z","timestamp":1794020937492,"version":"4.8.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94314-5","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:07:40Z","timestamp":1744114060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection"],"prefix":"10.1038","volume":"15","author":[{"given":"Anna L.","family":"Beukenhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keira L.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Frallicciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Koldijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette A. H. M.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A. S.","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Fischinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Julg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco M.","family":"Klap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa M.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Magyarics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faez A. Nait","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vintus","family":"Okonkwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larance","family":"Ronsard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Temperton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Vietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanin","family":"Wichapong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertjan","family":"Ziere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lingwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Goudsmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"94314_CR1","unstructured":"World Health Organization. Influenza (Seasonal)\u2014Fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal) (2023)."},{"key":"94314_CR2","unstructured":"World Health Organization. Influenza (Avian and other zoonotic)\u2014Fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(avian-and-other-zoonotic) (2023)."},{"key":"94314_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06136-y","author":"C Momont","year":"2023","unstructured":"Momont, C. et al. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. Nature https:\/\/doi.org\/10.1038\/s41586-023-06136-y (2023).","journal-title":"Nature"},{"key":"94314_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/vaccines9020125","volume":"9","author":"M Sangesland","year":"2021","unstructured":"Sangesland, M. & Lingwood, D. Antibody focusing to conserved sites of vulnerability: The immunological pathways for \u2018universal\u2019 influenza vaccines. Vaccines (Basel) 9, 125 (2021).","journal-title":"Vaccines (Basel)"},{"key":"94314_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41541-021-00417-1","volume":"6","author":"TM Caradonna","year":"2021","unstructured":"Caradonna, T. M. & Schmidt, A. G. Protein engineering strategies for rational immunogen design. NPJ Vaccines 6, 154 (2021).","journal-title":"NPJ Vaccines"},{"issue":"337","key":"94314_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"1979","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 1979(337), 1343\u20131348 (2012).","journal-title":"Science"},{"key":"94314_CR7","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1038\/s41598-024-53049-5","volume":"14","author":"AL Beukenhorst","year":"2024","unstructured":"Beukenhorst, A. L. et al. A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration. Sci. Rep. 14, 3818 (2024).","journal-title":"Sci. Rep."},{"key":"94314_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.01603-17","volume":"91","author":"TC Sutton","year":"2017","unstructured":"Sutton, T. C. et al. In vitro neutralization is not predictive of prophylactic efficacy of broadly neutralizing monoclonal antibodies CR6261 and CR9114 against lethal H2 influenza virus challenge in mice. J. Virol. 91, 10\u20131128 (2017).","journal-title":"J. Virol."},{"key":"94314_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.immuni.2019.09.001","volume":"51","author":"M Sangesland","year":"2019","unstructured":"Sangesland, M. et al. Germline-encoded affinity for cognate antigen enables vaccine amplification of a human broadly neutralizing response against influenza virus. Immunity 51, 735-749.e8 (2019).","journal-title":"Immunity"},{"key":"94314_CR10","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.immuni.2022.07.006","volume":"55","author":"M Sangesland","year":"2022","unstructured":"Sangesland, M. et al. Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus. Immunity 55, 1693-1709.e8 (2022).","journal-title":"Immunity"},{"key":"94314_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.immuni.2024.03.022","volume":"57","author":"R Ray","year":"2024","unstructured":"Ray, R. et al. Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses. Immunity 57, 1141-1159.e11 (2024).","journal-title":"Immunity"},{"issue":"333","key":"94314_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1204839","volume":"1979","author":"DC Ekiert","year":"2011","unstructured":"Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 1979(333), 843\u2013850 (2011).","journal-title":"Science"},{"key":"94314_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","volume":"21","author":"G Pantaleo","year":"2022","unstructured":"Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S. & Perez, L. Antibodies to combat viral infections: Development strategies and progress. Nat. Rev. Drug Discov. 21, 676\u2013696 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"94314_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","volume":"47","author":"S Bournazos","year":"2017","unstructured":"Bournazos, S. & Ravetch, J. V. Fc\u03b3 receptor function and the design of vaccination strategies. Immunity 47, 224\u2013233 (2017).","journal-title":"Immunity"},{"key":"94314_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fimmu.2019.00440","volume":"10","author":"CM Boudreau","year":"2019","unstructured":"Boudreau, C. M. & Alter, G. Extra-neutralizing FcR-mediated antibody functions for a universal influenza vaccine. Front. Immunol. 10, 440 (2019).","journal-title":"Front. Immunol."},{"key":"94314_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn, F. & Ravetch, J. V. Fc\u03b3 receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34\u201347 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"94314_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/intimm\/dxx025","volume":"29","author":"S Bournazos","year":"2017","unstructured":"Bournazos, S. & Ravetch, J. V. Diversification of IgG effector functions. Int. Immunol. 29, 303\u2013310 (2017).","journal-title":"Int. Immunol."},{"key":"94314_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2018.1489947","volume":"14","author":"R Rudraraju","year":"2018","unstructured":"Rudraraju, R. & Subbarao, K. Passive immunization with influenza haemagglutinin specific monoclonal antibodies. Hum. Vaccin. Immunother. 14, 1\u20139. https:\/\/doi.org\/10.1080\/21645515.2018.1489947 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"94314_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.coviro.2016.03.002","volume":"17","author":"A Cho","year":"2016","unstructured":"Cho, A. & Wrammert, J. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Curr. Opin. Virol. 17, 110\u2013115. https:\/\/doi.org\/10.1016\/j.coviro.2016.03.002 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"94314_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.coviro.2016.12.002","volume":"22","author":"HA Vanderven","year":"2017","unstructured":"Vanderven, H. A., Jegaskanda, S., Wheatley, A. K. & Kent, S. J. Antibody-dependent cellular cytotoxicity and influenza virus. Curr. Opin. Virol. 22, 89\u201396 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"94314_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm.3443","volume":"20","author":"DJ Dilillo","year":"2014","unstructured":"Dilillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143\u2013151 (2014).","journal-title":"Nat. Med."},{"key":"94314_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.00052-20","volume":"94","author":"A Vigil","year":"2020","unstructured":"Vigil, A., Frias-Staheli, N., Carabeo, T. & Wittekind, M. Airway delivery of anti-influenza monoclonal antibodies results in enhanced antiviral activities and enables broad-coverage combination therapies. J. Virol. 94, 10\u20131128 (2020).","journal-title":"J. Virol."},{"key":"94314_CR23","doi-asserted-by":"publisher","first-page":"1049134","DOI":"10.3389\/fviro.2022.1049134","volume":"2","author":"AL Beukenhorst","year":"2022","unstructured":"Beukenhorst, A. L. et al. The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection. Front. Virol. 2, 1049134 (2022).","journal-title":"Front. Virol."},{"key":"94314_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"94314_CR25","doi-asserted-by":"publisher","first-page":"11931","DOI":"10.1073\/pnas.1609316113","volume":"113","author":"W He","year":"2016","unstructured":"He, W. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl. Acad. Sci. 113, 11931\u201311936 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"333","key":"94314_CR26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","volume":"1979","author":"D Corti","year":"2011","unstructured":"Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 1979(333), 850\u2013856 (2011).","journal-title":"Science"},{"key":"94314_CR27","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.1038\/s41467-023-40699-8","volume":"14","author":"CM Boudreau","year":"2023","unstructured":"Boudreau, C. M. et al. Antibody-mediated NK cell activation as a correlate of immunity against influenza infection. Nat. Commun. 14, 5170 (2023).","journal-title":"Nat. Commun."},{"issue":"387","key":"94314_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1126\/science.ado6481","volume":"1979","author":"M Kanekiyo","year":"2025","unstructured":"Kanekiyo, M. et al. Pre-exposure antibody prophylaxis protects macaques from severe influenza. Science 1979(387), 534\u2013541 (2025).","journal-title":"Science"},{"key":"94314_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.coviro.2020.08.004","volume":"44","author":"R Liu","year":"2020","unstructured":"Liu, R., Sheng, Z., Huang, C., Wang, D. & Li, F. Influenza D virus. Curr. Opin. Virol. 44, 154\u2013161 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"94314_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s13238-015-0193-x","volume":"7","author":"M Wang","year":"2016","unstructured":"Wang, M. & Veit, M. Hemagglutinin-esterase-fusion (HEF) protein of influenza C virus. Protein Cell 7, 28\u201345 (2016).","journal-title":"Protein Cell"},{"key":"94314_CR31","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/s41467-021-21818-9","volume":"12","author":"S Halldorsson","year":"2021","unstructured":"Halldorsson, S., Sader, K., Turner, J., Calder, L. J. & Rosenthal, P. B. In situ structure and organization of the influenza C virus surface glycoprotein. Nat. Commun. 12, 1694 (2021).","journal-title":"Nat. Commun."},{"key":"94314_CR32","doi-asserted-by":"publisher","first-page":"e1007427","DOI":"10.1371\/journal.ppat.1007427","volume":"15","author":"S Saito","year":"2019","unstructured":"Saito, S. et al. IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody. PLoS Pathog. 15, e1007427 (2019).","journal-title":"PLoS Pathog."},{"key":"94314_CR33","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1073\/pnas.1503885112","volume":"112","author":"T Suzuki","year":"2015","unstructured":"Suzuki, T. et al. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proc. Natl. Acad. Sci. 112, 7809\u20137814 (2015).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"94314_CR34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/21645515.2018.1438791","volume":"14","author":"Y Terauchi","year":"2018","unstructured":"Terauchi, Y. et al. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration. Hum. Vaccin. Immunother. 14, 1351\u20131361 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"94314_CR35","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/scitranslmed.abf1555","volume":"13","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, 1555 (2021).","journal-title":"Sci. Transl. Med."},{"issue":"366","key":"94314_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"1979","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 1979(366), 499\u2013504 (2019).","journal-title":"Science"},{"key":"94314_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.01526-18","volume":"93","author":"Y-Q Chen","year":"2019","unstructured":"Chen, Y.-Q., Lan, L.Y.-L., Huang, M., Henry, C. & Wilson, P. C. Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance. J. Virol. 93, 10\u20131128 (2019).","journal-title":"J. Virol."},{"key":"94314_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.02281-16","volume":"8","author":"M Rajendran","year":"2017","unstructured":"Rajendran, M. et al. Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: Evidence for original antigenic sin. mBio 8, 10\u20131128 (2017).","journal-title":"mBio"},{"key":"94314_CR39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3390\/vaccines10091520","volume":"10","author":"KAS da Costa","year":"2022","unstructured":"da Costa, K. A. S. et al. Influenza A (N1\u2013N9) and Influenza B (B\/Victoria and B\/Yamagata) neuraminidase pseudotypes as tools for pandemic preparedness and improved influenza vaccine design. Vaccines (Basel) 10, 1520 (2022).","journal-title":"Vaccines (Basel)"},{"key":"94314_CR40","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.4049\/jimmunol.147.8.2657","volume":"147","author":"J Lund","year":"1991","unstructured":"Lund, J. et al. Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG. J. Immunol. 147, 2657\u20132662 (1991).","journal-title":"J. Immunol."},{"key":"94314_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/eji.1830230216","volume":"23","author":"S Bolt","year":"1993","unstructured":"Bolt, S. et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23, 403\u2013411 (1993).","journal-title":"Eur. J. Immunol."},{"key":"94314_CR42","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1128\/AAC.00290-15","volume":"59","author":"VH Leyva-Grado","year":"2015","unstructured":"Leyva-Grado, V. H., Tan, G. S., Leon, P. E., Yondola, M. & Palese, P. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob. Agents Chemother. 59, 4162\u20134172 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94314_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/19420862.2015.1111497","volume":"8","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Influence of molecular size on tissue distribution of antibody fragments. MAbs 8, 113\u2013119 (2016).","journal-title":"MAbs"},{"key":"94314_CR44","doi-asserted-by":"publisher","first-page":"e4260","DOI":"10.1093\/cid\/ciaa1725","volume":"73","author":"A Han","year":"2021","unstructured":"Han, A. et al. Safety and efficacy of CR6261 in an influenza A H1N1 healthy human challenge model. Clin. Infect. Dis. 73, e4260\u2013e4268 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"94314_CR45","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","volume":"40","author":"E Hershberger","year":"2019","unstructured":"Hershberger, E. et al. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine 40, 574\u2013582 (2019).","journal-title":"EBioMedicine"},{"key":"94314_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01154-17","volume":"61","author":"JM McBride","year":"2017","unstructured":"McBride, J. M. et al. Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human Influenza A virus challenge model. Antimicrob. Agents Chemother. 61, 10\u20131128 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94314_CR47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/pharmaceutics16101259","volume":"16","author":"P Jagdale","year":"2024","unstructured":"Jagdale, P., Verma, A. & Shah, D. K. Pulmonary pharmacokinetics of antibody and antibody fragments following systemic and local administration in mice. Pharmaceutics 16, 1259 (2024).","journal-title":"Pharmaceutics"},{"key":"94314_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.02269-17","volume":"62","author":"A Vigil","year":"2018","unstructured":"Vigil, A. et al. Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses. Antimicrob. Agents Chemother. 62, 10\u20131128 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94314_CR49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jmb.2015.09.014","volume":"428","author":"GCP van Zundert","year":"2016","unstructured":"van Zundert, G. C. P. et al. The HADDOCK2.2 web server: User-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 428, 720\u2013725 (2016).","journal-title":"J. Mol. Biol."},{"key":"94314_CR50","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1021\/acs.jmedchem.5b01952","volume":"59","author":"K Wichapong","year":"2016","unstructured":"Wichapong, K. et al. Structure-based design of peptidic inhibitors of the interaction between CC chemokine ligand 5 (CCL5) and human neutrophil peptides 1 (HNP1). J. Med. Chem. 59, 4289\u20134301 (2016).","journal-title":"J. Med. Chem."},{"key":"94314_CR51","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.csbj.2021.01.026","volume":"19","author":"K Wichapong","year":"2021","unstructured":"Wichapong, K. et al. Structure-based peptide design targeting intrinsically disordered proteins: Novel histone H4 and H2A peptidic inhibitors. Comput. Struct. Biotechnol. J. 19, 934\u2013948 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"94314_CR52","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","volume":"63","author":"DA Case","year":"2023","unstructured":"Case, D. A. et al. AmberTools. J. Chem. Inf. Model. 63, 6183\u20136191 (2023).","journal-title":"J. Chem. Inf. Model."},{"key":"94314_CR53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1743-422X-2-84","volume":"2","author":"E Zielinska","year":"2005","unstructured":"Zielinska, E. et al. Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis. Virol. J. 2, 84 (2005).","journal-title":"Virol. J."},{"key":"94314_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/mps1010008","volume":"1","author":"F Ferrara","year":"2018","unstructured":"Ferrara, F. & Temperton, N. Pseudotype neutralization assays: From laboratory bench to data analysis. Methods Protoc. 1, 8 (2018).","journal-title":"Methods Protoc."},{"key":"94314_CR55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/23974","volume":"396","author":"PB Rosenthal","year":"1998","unstructured":"Rosenthal, P. B. et al. Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus. Nature 396, 92\u201396 (1998).","journal-title":"Nature"},{"key":"94314_CR56","doi-asserted-by":"publisher","first-page":"e1005411","DOI":"10.1371\/journal.ppat.1005411","volume":"12","author":"H Song","year":"2016","unstructured":"Song, H. et al. An open receptor-binding cavity of hemagglutinin-esterase-fusion glycoprotein from newly-identified Influenza D virus: Basis for its broad cell tropism. PLoS Pathog. 12, e1005411 (2016).","journal-title":"PLoS Pathog."},{"key":"94314_CR57","doi-asserted-by":"publisher","first-page":"497123","DOI":"10.1128\/mBio.02810-18","volume":"10","author":"KS Corbett","year":"2019","unstructured":"Corbett, K. S. et al. Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio 10, 497123 (2019).","journal-title":"mBio"},{"key":"94314_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nprot.2016.009","volume":"11","author":"GC Weaver","year":"2016","unstructured":"Weaver, G. C. et al. In vitro reconstitution of B cell receptor\u2013antigen interactions to evaluate potential vaccine candidates. Nat. Protoc. 11, 193\u2013213 (2016).","journal-title":"Nat. Protoc."},{"key":"94314_CR59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102\u2013106 (2013).","journal-title":"Nature"},{"issue":"329","key":"94314_CR60","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"1979","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 1979(329), 856\u2013861 (2010).","journal-title":"Science"},{"key":"94314_CR61","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1038\/s41467-023-40918-2","volume":"14","author":"L Ronsard","year":"2023","unstructured":"Ronsard, L. et al. Engaging an HIV vaccine target through the acquisition of low B cell affinity. Nat. Commun. 14, 5249 (2023).","journal-title":"Nat. Commun."},{"key":"94314_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jee\/18.2.265a","volume":"18","author":"WS Abbott","year":"1925","unstructured":"Abbott, W. S. A method of computing the effectiveness of an insecticide. J. Econ. Entomol. 18, 265\u2013267 (1925).","journal-title":"J. Econ. Entomol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94314-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:07:42Z","timestamp":1744114062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94314-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94314"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94314-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L.B., K.L.R., J.F., M.H.K, C.M.B., J.C., B.A.d.J., S.F., J.M.K., C.M.K., H.V., Z.M., and B.Z. disclose that they are employees of Leyden Laboratories with stock options in this company. B.J. is an advisor to Leyden Laboratories with stock options in this company; J.G. is an advisor to Leyden Laboratories with shares and stock options in this company. Other authors have not reported any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10309"}}